COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

March 7, 2019
precisionFDA/NCI-CPTAC Challenge Top Performers to Present at RECOMB2019 DREAM Satellite Conference

In February 2019, the precisionFDA and the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) (in coordination with DREAM Challenges) proudly announced the best performers in the first-ever...
March 4, 2019
CPTAC Researchers Develop A Freely Available Database for Phosphosite-Specific Signature Analysis

It is no coincidence that one cellular process is mentioned time and time again in discussions of cell-signaling pathways in cancer - that is phosphorylation. Since its discovery, it has come to be recognized as a global regulator of many intracellular processes such as growth, proliferation, and...
February 25, 2019
Best Performers Announced! - precisionFDA NCI-CPTAC Crowdsourced Multi-omics Sample Mislabeling Big Data Challenge

In biomedical research, sample mislabeling, or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample...
February 19, 2019
Researchers Team Up to Catalog the Landscape of Circular RNA in Cancer

University of Michigan Rogel Cancer Center researchers Arul Chinnaiyan, Alexey Nesvizhskii and colleagues have recently teamed up to catalog circular RNA (circRNA) in multiple cancers and conducted initial research that suggests these stable structures could serve as cancer markers in blood or urine...
February 15, 2019
CPTAC Develops PepQuery for Novel Peptide Identification and Validation

Integrative proteogenomic methods use mass spectrometry (MS)-based proteomic database for identifying new genomic alterations and validating novel protein sequences as potential disease biomarkers or therapeutic targets. The customized database approach is time consuming and not feasible for real-...
January 28, 2019
Update on Behalf of NCI’s Cancer Imaging Program (New CPTAC Histopathology Images)

Built on a continuous partnership between National Cancer Institute’s (NCI’s) Cancer Imaging Program and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), NCI’s The Cancer Imaging Archive (TCIA) releases a newly improved CPTAC histopathology interface. The interface hosts histopathology...
January 24, 2019
NCI Proteomics Assay Portal Releases 660 Mouse MRM-MS Plasma Assays

Built on a continuous partnership between National Cancer Institute (NCI) and the University of Victoria Genome British Columbia Proteomics Centre, NCI’s CPTAC Assay Portal releases 660 mouse multiple reaction monitoring-mass spectrometry (MRM-MS) plasma assays...
January 16, 2019
ICPC Korea University Team Proteogenomically Characterizes Early-Onset Gastric Cancer


The incidence of early-onset gastric cancer (EOGC), a type of cancer that occurs in younger patients and found throughout the stomach, is markedly elevated in the Republic of Korea. As a country with the highest rates worldwide in both sexes, there is a need to identify molecular signatures...
December 20, 2018
Proteogenomics Approach Identifies DPYSL3 Gene in Triple-Negative Breast Cancer

Claudin-Low (CLOW) tumors are classified as a subset of triple-negative breast cancers and account for a minority of breast cancer cases. But until now, there has been little study of their unique biological features. Understanding the biology of CLOW tumors is important for designing targeted...
December 14, 2018
Final Announcement: PrecisionFDA NCI-CPTAC Multi-omics Challenge Ends in Four Days

The NCI-CPTAC Multi-omics Enabled Sample Mislabeling Correction Challenge sub-challenge 2 closes on December 19 at 07:59:59 UTC. Just four days left to submit your computational algorithms. Remember, if...

Pages

more

View all News and Announcements

NIH…Turning Discovery Into Health®